RNA (Avidity Biosciences Inc) Return on Sales by Gross Profit

Official company branding of Avidity Biosciences Inc (RNA)

Avidity Biosciences (RNA) is developing RNA therapeutics to treat rare muscle pathologies, leveraging a unique drug delivery method. Changes in gross margin confirm this potential, where the value of 97.50 serves as the current indicator. However, stringent regulatory oversight and the capital-intensive nature of development create barriers. The business currently relies on external investment, as full-scale commercial products have not yet been brought to market.

Gross Profitability: Avidity Biosciences Inc (RNA) for 07/04/2022 - 11/19/2026

Financial and market metric breakdowns for Avidity Biosciences Inc (RNA)

Basic company analysis:RNA - Avidity Biosciences Inc
Core merchandise of Avidity Biosciences, Inc.

Gross margin measures production efficiency by determining the portion of revenue remaining after direct costs, allowing investors to filter out noise and assess the actual profitability of assets. An analysis of the historical gross margin of Avidity Biosciences (RNA) demonstrates the financial resilience of the business, where the success of oligonucleotide clinical trials and regulatory milestones drive the company's valuation independently of global macroeconomic cycles.

Main competitors

Return on Gross Profit Tempus AI Inc|QGEN (Qiagen NV) - Gross Margin|Return on Gross Profit Ionis Pharma (IONS)|Gross Profitability Repligen Corp (RGEN)|CRSP - Gross Profit Margin|GeneDx - Return on Gross Profit|Gross Profit Rate RARE|Beam Tx - Gross Margin|SRPT - Gross Margin|TWST (Twist Bio) - Return on Gross Profit|Gross Return on Sales TXG|Return on Gross Profit NTLA|Stoke Therapeutics Inc (STOK) - Return on Sales by Gross Profit|Gross Margin BLFS|Gross Profitability WVE (Wave Life Sciences Corp)|Gross Profitability Maze Therapeutics MAZE|Gross Profit Rate SION|PRME - Gross Profitability|Return on Sales by Gross Profit Taysha TSHA|QURE: Gross Margin|Return on Gross Profit MeiraGTx PLC|RGNX (REGENXBIO Inc) - Gross Margin|solidbio.com (SLDB) - Return on Sales by Gross Profit|Gross Profitability Ocugen Corp (OCGN)|Pacific Biosciences of California, Inc. - Gross Return on Sales|Benitec Biopharma - Return on Gross Profit|DSGN: Gross Return on Sales|RCKT: Return on Gross Profit|FDMT - Gross Margin|LXEO: Gross Margin|Korro Bio Inc. - Gross Profit Rate|EDIT (editasmedicine.com) - Gross Margin|Gross Profitability SLN|Gross Profitability ProQR Therapeutics NV (PRQR)|Codexis - Gross Return on Sales|Gross Profitability Sangamo SGMO|NAUT: Gross Return on Sales|MGX: Return on Gross Profit|Gross Profit Margin Precision BioSciences|GBIO (generationbio.com) - Return on Gross Profit|Gross Profit Margin boundlessbio.com (BOLD)|XCUR (exicuretx.com) - Gross Margin|Gross Return on Sales IMNN (Imunon, Inc.)|Gross Margin PHIO|MBIO - Gross Profit Margin|Gross Margin RNAZ (TransCode Therapeutics)|bionanogenomics.com (BNGO) - Gross Profit Margin|Applied DNA - Gross Margin|Gross Profit Margin Bluebird Bio|ImmunoPrecise (IPA) - Gross Profitability|Gross Profitability Margin OMGA (Omega)|Gross Profitability Singular Genomics Systems|Gross Profit Margin regulusrx.com RGLS|Gross Profitability Syros Pharmaceuticals Inc. (SYRS)|Return on Sales by Gross Profit Codex DNA|Gross Profitability TRACON TCON|Unity Biotechnology, Inc - Gross Profitability